Business
-
Nephron Pharmaceuticals CEO Lou Kennedy spoke to local reporters in the company’s home state of South Carolina on March 17, 2020, describing the company’s efforts to increase production of its inhalation solutions and suspensions to… Read more . . .
-
Montreal-based Pharmascience has announced the launch of its pms-fluticasone propionate/salmeterol DPI in Canada for the treatment of asthma and COPD. The company says that the DPI uses the same device as Advair Diskus. According to… Read more . . .
-
Inhaled drug developer MannKind Corporation has announced that it “is committed to joining the global effort to overcome the COVID-19 crisis” and as a result “that it is adjusting research and development resources that were reserved… Read more . . .
-
Insmed has announced its submission of a new drug application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium… Read more . . .
-
According to the FDA, three DPIs marketed by Sunovion in the US have been discontinued as of March 10, 2020. Sunovion acquired the US rights to Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler, and Arcapta (indacaterol)… Read more . . .
-
According to Senzer, the company has obtained the IND application and data package for its inhaled dronabinol from its former partner, Insys Therapeutics, and will now move ahead with development for the treatment of side… Read more . . .
-
Mylan Pharmaceuticals has announced the launch of the Wixela Inhub fluticasone propionate/salmeterol DPI in Canada. According to the company, Health Canada approved Wixela Inhub, a generic version of Advair Diskus, in January 2020 for asthma and COPD.… Read more . . .
-
Neurelis has announced the launch of Valtoco diazepam nasal spray for the treatment of seizure clusters in the US. The FDA approved Valtoco for the treatment of acute repetitive seizures in epilepsy patients aged 6… Read more . . .
-
Hikma Pharmaceuticals has signed an agreement with Glenmark Pharmaceuticals for exclusive US rights to Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis, the companies said. According to the announcement, the… Read more . . .
-
Aradigm Corporation, which filed for bankruptcy in February 2019, said that it will sell all of its assets related to Lipoquin inhaled ciprofloxacin, Apulmiq (Linhaliq) dual release inhaled ciprofloxacin, and other inhaled ciprofloxacin candidates to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden